The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson’s Disease

Autor: Clive N. Svendsen, Helwig M, Nigel T. Maidment, Iris Lindberg, Yucer Nur, Zhan Shu, Di Monte D, Hoa A. Lam, Laperle Alexander

Publikováno v: Journal of Parkinson's Disease 12(5), 1463-1478 (2022). doi:10.3233/JPD-213053
J Parkinsons Dis

Parkinson’s disease is a devastating motor disorder involving the aberrant aggregation of the synaptic protein synuclein (aSyn) and degeneration of the nigrostriatal dopaminergic tract. We previously showed that proSAAS, a small secreted chaperone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6cd3ba9f0dfbd58bcf8b93d3bd27c1d
https://doi.org/10.3233/jpd-213053

Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice

Autor: Laura Malz, Eva M Szego, Nadine Bernhardt, Angela Rösen-Wolff, Björn H Falkenburger, Hella Luksch

Publikováno v: eLife 11, e81943 (2022). doi:10.7554/eLife.81943

Stimulator of interferon genes (STING) is activated after detection of cytoplasmic dsDNA by cGAS (cyclic GMP-AMP synthase) as part of the innate immunity defence against viral pathogens. STING binds TANK-binding kinase 1 (TBK1). TBK1 mutations are as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ebd0eda879f38af5d4f9039f24f7b0
https://pubmed.ncbi.nlm.nih.gov/36314770

Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells

Autor: Marvin Oldrati, Daria Messelodi, Ivana Nikić-Spiegel, Maria-Jose Perez, Cong Yu, Aleksandra Arsić, Thomas Gasser, David C. Schöndorf, Vasiliki Panagiotakopoulou, Dina Ivanyuk, Meike Jakobi, Ruggiero Pio Cassatella, Silvia De Cicco, Michela Deleidi, Wadood Haq, Nicole Schneiderhan-Marra

Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Nature Communications
Nature Communications 11(1), 5163 (2020). doi:10.1038/s41467-020-18755-4

Parkinson’s disease-associated kinase LRRK2 has been linked to IFN type II (IFN-γ) response in infections and to dopaminergic neuronal loss. However, whether and how LRRK2 synergizes with IFN-γ remains unclear. In this study, we employed dopamine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ac34786697a3cff0d6b047aa772ef7
http://link.springer.com/article/10.1038/s41467-020-18755-4

Connexin43 inhibition attenuated dopaminergic neuronal loss in the lipopolysaccharide-induced mice model of Parkinson's disease

Autor: Yujia Zhao, Yuze Qi, Qingru Li, Huihui Quan, Dan Liu, Hui Zhou

Publikováno v: Neuroscience letters 771, 136471 (2022). doi:10.1016/j.neulet.2022.136471

Studies using in vitro Parkinson's disease (PD) models have found that lipopolysaccharide (LPS) induced reduction of connexin 43 (Cx43) gap junction communication and elevation of hemichannel function, which could cause neurotoxicity directly and ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5747b2eb7ca27f8960d4853cef325ae
https://pub.dzne.de/record/163619

Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models

Autor: Pingping Song, Lena F. Burbulla, Dimitri Krainc, Jianbin Zheng, Michaela E. Johnson, Weilan Jiang, Patrik Brundin

Publikováno v: JCI insight 6(19), e148649 (2021). doi:10.1172/jci.insight.148649
JCI Insight

Current treatments for Parkinson's disease (PD) provide only symptomatic relief, with no disease-modifying therapies identified to date. Repurposing FDA-approved drugs to treat PD could significantly shorten the time needed for and reduce the costs o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0e57b68f83b8651105ddd9418b71dd
https://doi.org/10.1172/jci.insight.148649